{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:57:47Z","timestamp":1793642267134,"version":"4.5.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific and Technological Project of Beijing Tongzhou District Plan","award":["KJ2024CX058"],"award-info":[{"award-number":["KJ2024CX058"]}]},{"name":"Scientific and Technological Project of Beijing Tongzhou District Plan","award":["KJ2024CX058"],"award-info":[{"award-number":["KJ2024CX058"]}]},{"name":"Scientific and Technological Innovation Team Project of Hebei Innovation Capability Enhancement Plan","award":["No. 235A2601D"],"award-info":[{"award-number":["No. 235A2601D"]}]},{"name":"Scientific and Technological Innovation Team Project of Hebei Innovation Capability Enhancement Plan","award":["No. 235A2601D"],"award-info":[{"award-number":["No. 235A2601D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09082-x","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:20:04Z","timestamp":1753266004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"68","author":[{"given":"Ziyan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"7","key":"9082_CR1","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.3390\/ijms24076578","volume":"24","author":"D Accapezzato","year":"2023","unstructured":"Accapezzato D, Caccavale R, Paroli MP et al (2023) Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus[J\/OL]. Int J Mol Sci 24(7):6578. https:\/\/doi.org\/10.3390\/ijms24076578","journal-title":"Int J Mol Sci"},{"key":"9082_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","volume":"67","author":"M Postal","year":"2020","unstructured":"Postal M, Vivaldo JF, Fernandez-Ruiz R et al (2020) Type I interferon in the pathogenesis of systemic lupus erythematosus[J\/OL]. Curr Opin Immunol 67:87\u201394. https:\/\/doi.org\/10.1016\/j.coi.2020.10.014","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"9082_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update[J\/OL]. Ann Rheum Dis 83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9082_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3899\/jrheum.160214","volume":"45","author":"HL Chen","year":"2018","unstructured":"Chen HL, Shen LJ, Hsu PN et al (2018) Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study[J\/OL]. J Rheumatol 45(1):83\u201389. https:\/\/doi.org\/10.3899\/jrheum.160214","journal-title":"J Rheumatol"},{"key":"9082_CR5","doi-asserted-by":"publisher","unstructured":"STOHL W, SCHWARTING A, OKADA M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty\u2010Two\u2013Week Randomized, Double\u2010Blind, Placebo\u2010Controlled Study[J\/OL]. Arthritis & Rheumatology (Hoboken, N.j.), 2017, 69(5): 1016\u20131027. https:\/\/doi.org\/10.1002\/art.40049.","DOI":"10.1002\/art.40049"},{"key":"9082_CR6","unstructured":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus | New England Journal of Medicine[EB\/OL]. [2025\u201303\u201302]. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1912196."},{"key":"9082_CR7","doi-asserted-by":"publisher","unstructured":"CLOWSE M E B, WALLACE D J, FURIE R A, et al. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double\u2010Blind, Placebo\u2010Controlled Trials[J\/OL]. Arthritis & Rheumatology (Hoboken, N.j.), 2017, 69(2): 362\u2013375. https:\/\/doi.org\/10.1002\/art.39856.","DOI":"10.1002\/art.39856"},{"key":"9082_CR8","doi-asserted-by":"publisher","unstructured":"TAO M J, CHENG P, JIN L R, et al. The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis[J\/OL]. Pakistan Journal of Medical Sciences, 2019, 35(6): 1680\u20131686. https:\/\/doi.org\/10.12669\/pjms.35.6.771.","DOI":"10.12669\/pjms.35.6.771"},{"key":"9082_CR9","doi-asserted-by":"publisher","unstructured":"WATT J, DEL GIOVANE C. Network Meta-Analysis[J\/OL]. Methods in Molecular Biology (Clifton, N.J.), 2022, 2345: 187\u2013201. https:\/\/doi.org\/10.1007\/978-1-0716-1566-9_12.","DOI":"10.1007\/978-1-0716-1566-9_12"},{"key":"9082_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews[J\/OL]. BMJ (Clinical research ed) 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ (Clinical research ed)"},{"issue":"11","key":"9082_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J\/OL]. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"issue":"3","key":"9082_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1056\/NEJMe1915490","volume":"382","author":"JE Salmon","year":"2020","unstructured":"Salmon JE, Niewold TB (2020) A Successful Trial for Lupus - How Good Is Good Enough?[J\/OL]. N Engl J Med 382(3):287\u2013288. https:\/\/doi.org\/10.1056\/NEJMe1915490","journal-title":"N Engl J Med"},{"issue":"1","key":"9082_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2013-000005","volume":"1","author":"A Thanou","year":"2014","unstructured":"Thanou A, Chakravarty E, James JA et al (2014) Which outcome measures in SLE clinical trials best reflect medical judgment?[J\/OL]. Lupus Science & Medicine 1(1):e000005. https:\/\/doi.org\/10.1136\/lupus-2013-000005","journal-title":"Lupus Science & Medicine"},{"key":"9082_CR14","doi-asserted-by":"publisher","unstructured":"LUIJTEN K M a. C, TEKSTRA J, BIJLSMA J W J, et al. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment[J\/OL]. Autoimmunity Reviews, 2012, 11(5): 326\u2013329. https:\/\/doi.org\/10.1016\/j.autrev.2011.06.011.","DOI":"10.1016\/j.autrev.2011.06.011"},{"key":"9082_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials[J\/OL]. BMJ (Clinical research ed) 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ (Clinical research ed)"},{"issue":"3","key":"9082_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H (2018) Quantifying publication bias in meta-analysis[J\/OL]. Biometrics 74(3):785\u2013794. https:\/\/doi.org\/10.1111\/biom.12817","journal-title":"Biometrics"},{"issue":"4","key":"9082_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00273171.2022.2115965","volume":"58","author":"Y Liu","year":"2023","unstructured":"Liu Y, B\u00e9liveau A, Wei Y et al (2023) A Gentle Introduction to Bayesian Network Meta-Analysis Using an Automated R Package[J\/OL]. Multivar Behav Res 58(4):706\u2013722. https:\/\/doi.org\/10.1080\/00273171.2022.2115965","journal-title":"Multivar Behav Res"},{"issue":"3","key":"9082_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","volume":"151","author":"T Nopsopon","year":"2023","unstructured":"Nopsopon T, Lassiter G, Chen ML et al (2023) Comparative Efficacy of Tezepelumab to Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-analysis[J\/OL]. J Allergy Clin Immunol 151(3):747\u2013755. https:\/\/doi.org\/10.1016\/j.jaci.2022.11.021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9082_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/icvts\/ivy163","volume":"27","author":"F Barili","year":"2018","unstructured":"Barili F, Parolari A, Kappetein PA et al (2018) Statistical Primer: heterogeneity, random- or fixed-effects model analyses?[J\/OL]. Interact Cardiovasc Thorac Surg 27(3):317\u2013321. https:\/\/doi.org\/10.1093\/icvts\/ivy163","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"3","key":"9082_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae SC, Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J\/OL]. Ann Rheum Dis 77(3):355\u2013363. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211631","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9082_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial[J\/OL]. Ann Rheum Dis 83(4):475\u2013487. https:\/\/doi.org\/10.1136\/ard-2023-224854","journal-title":"Ann Rheum Dis"},{"key":"9082_CR22","doi-asserted-by":"publisher","unstructured":"GINZLER E, GUEDES BARBOSA L S, D\u2019CRUZ D, et al. Phase III \/ IV , Randomized, Fifty\u2010Two \u2013Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus[J\/OL]. Arthritis & Rheumatology, 2022, 74(1): 112\u2013123. https:\/\/doi.org\/10.1002\/art.41900.","DOI":"10.1002\/art.41900"},{"issue":"2","key":"9082_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT et al (2017) Anifrolumab, an Anti\u2013Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus[J\/OL]. Arthritis & Rheumatology 69(2):376\u2013386. https:\/\/doi.org\/10.1002\/art.39962","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"9082_CR24","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial[J\/OL]. The Lancet Rheumatology 1(4):e208\u2013e219. https:\/\/doi.org\/10.1016\/S2665-9913(19)30076-1","journal-title":"The Lancet Rheumatology"},{"issue":"3","key":"9082_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of Anifrolumab in Active Systemic Lupus Erythematosus[J\/OL]. N Engl J Med 382(3):211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"issue":"2","key":"9082_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S et al (2018) Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four\u2013Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase II b Study[J\/OL]. Arthritis & Rheumatology 70(2):266\u2013276. https:\/\/doi.org\/10.1002\/art.40360","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"9082_CR27","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D et al (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)[J\/OL]. Ann Rheum Dis 74(11):2006\u20132015. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205067","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"9082_CR28","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie RA, Leon G, Thomas M et al (2015) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study[J\/OL]. Ann Rheum Dis 74(9):1667\u20131675. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205144","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9082_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M et al (2018) Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial[J\/OL]. Ann Rheum Dis 77(6):883\u2013889. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213032","journal-title":"Ann Rheum Dis"},{"issue":"10143","key":"9082_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial[J\/OL]. The Lancet 392(10143):222\u2013231. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1","journal-title":"The Lancet"},{"issue":"10381","key":"9082_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)[J\/OL]. The Lancet 401(10381):1001\u20131010. https:\/\/doi.org\/10.1016\/S0140-6736(22)02607-1","journal-title":"The Lancet"},{"issue":"10381","key":"9082_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)[J\/OL]. The Lancet 401(10381):1011\u20131019. https:\/\/doi.org\/10.1016\/S0140-6736(22)02546-6","journal-title":"The Lancet"},{"issue":"2","key":"9082_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT et al (2023) Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial[J\/OL]. Arthritis & Rheumatology 75(2):242\u2013252. https:\/\/doi.org\/10.1002\/art.42391","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"9082_CR34","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, Bruce IN, D\u00f6rner T et al (2021) Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus[J\/OL]. Rheumatology 60(11):5397\u20135407. https:\/\/doi.org\/10.1093\/rheumatology\/keab381","journal-title":"Rheumatology"},{"issue":"1","key":"9082_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ, Kalunian K, Petri MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study[J\/OL]. Ann Rheum Dis 73(1):183\u2013190. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202760","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"9082_CR36","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg D, Furie R, Jones NS et al (2021) Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u2019s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial[J\/OL]. Arthritis & Rheumatology 73(10):1835\u20131846. https:\/\/doi.org\/10.1002\/art.41811","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"9082_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","volume":"79","author":"FA Houssiau","year":"2020","unstructured":"Houssiau FA, Thanou A, Mazur M et al (2020) IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study[J\/OL]. Ann Rheum Dis 79(3):347\u2013355. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216379","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"9082_CR38","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill JT, Werth VP, Furie R et al (2022) Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus[J\/OL]. N Engl J Med 386(11):1034\u20131045. https:\/\/doi.org\/10.1056\/NEJMoa2106535","journal-title":"N Engl J Med"},{"issue":"1","key":"9082_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001113","volume":"11","author":"DJ Burge","year":"2024","unstructured":"Burge DJ, Werth VP, Boackle SA et al (2024) Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132[J\/OL]. Lupus Science & Medicine 11(1):e001113. https:\/\/doi.org\/10.1136\/lupus-2023-001113","journal-title":"Lupus Science & Medicine"},{"issue":"1","key":"9082_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","volume":"75","author":"KC Kalunian","year":"2016","unstructured":"Kalunian KC, Merrill JT, Maciuca R et al (2016) A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)[J\/OL]. Ann Rheum Dis 75(1):196\u2013202. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206090","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9082_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K et al (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study[J\/OL]. Ann Rheum Dis 75(2):323\u2013331. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207653","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9082_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill JT, van Vollenhoven RF, Buyon JP et al (2016) Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study[J\/OL]. Ann Rheum Dis 75(2):332\u2013340. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207654","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"9082_CR43","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP et al (2016) Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study[J\/OL]. Ann Rheum Dis 75(11):1909\u20131916. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208562","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"9082_CR44","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/art.41179","volume":"72","author":"RF van Vollenhoven","year":"2020","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC et al (2020) Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus[J\/OL]. Arthritis & Rheumatology 72(5):761\u2013768. https:\/\/doi.org\/10.1002\/art.41179","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"9082_CR45","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","volume":"81","author":"RF van Vollenhoven","year":"2022","unstructured":"van Vollenhoven RF, Kalunian KC, D\u00f6rner T et al (2022) Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus[J\/OL]. Ann Rheum Dis 81(11):1556\u20131563. https:\/\/doi.org\/10.1136\/ard-2022-222858","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9082_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan L, Lu MP, Wang JH et al (2020) Immunological pathogenesis and treatment of systemic lupus erythematosus[J\/OL]. World Journal of Pediatrics 16(1):19\u201330. https:\/\/doi.org\/10.1007\/s12519-019-00229-3","journal-title":"World Journal of Pediatrics"},{"issue":"2","key":"9082_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","volume":"27","author":"ME Allen","year":"2021","unstructured":"Allen ME, Rus V, Szeto GL (2021) Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies[J\/OL]. Trends Mol Med 27(2):152\u2013171. https:\/\/doi.org\/10.1016\/j.molmed.2020.09.009","journal-title":"Trends Mol Med"},{"issue":"2","key":"9082_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001331","volume":"11","author":"A Nordmann-Gomes","year":"2024","unstructured":"Nordmann-Gomes A, Cojuc-Konigsberg G, Hern\u00e1ndez-Andrade A et al (2024) Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups[J\/OL]. Lupus Science & Medicine 11(2):e001331. https:\/\/doi.org\/10.1136\/lupus-2024-001331","journal-title":"Lupus Science & Medicine"},{"issue":"1","key":"9082_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaci.2021.11.005","volume":"149","author":"KA Owen","year":"2022","unstructured":"Owen KA, Grammer AC, Lipsky PE (2022) Deconvoluting the heterogeneity of SLE: The contribution of ancestry[J\/OL]. J Allergy Clin Immunol 149(1):12\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2021.11.005","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9082_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","volume":"76","author":"R van Vollenhoven","year":"2017","unstructured":"van Vollenhoven R, Voskuyl A, Bertsias G et al (2017) A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J\/OL]. Ann Rheum Dis 76(3):554\u2013561. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209519","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9082_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force[J\/OL]. Lupus Science & Medicine 8(1):e000538. https:\/\/doi.org\/10.1136\/lupus-2021-000538","journal-title":"Lupus Science & Medicine"},{"key":"9082_CR52","doi-asserted-by":"publisher","unstructured":"PARRA S\u00c1NCHEZ A R, VAN VOLLENHOVEN R F, MORAND E F, et al. Targeting DORIS Remission and LLDAS in SLE: A Review[J\/OL]. Rheumatology and Therapy, 2023, 10(6): 1459\u20131477. https:\/\/doi.org\/10.1007\/s40744-023-00601-w.","DOI":"10.1007\/s40744-023-00601-w"},{"key":"9082_CR53","doi-asserted-by":"publisher","unstructured":"KIROU K A, DALL`ERA M, ARANOW C, et al. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment[J\/OL]. Frontiers in Immunology, 2022, 13: 980079. https:\/\/doi.org\/10.3389\/fimmu.2022.980079.","DOI":"10.3389\/fimmu.2022.980079"},{"key":"9082_CR54","doi-asserted-by":"publisher","unstructured":"SHI F, Xue ,Ran, Zhou ,Xuexiao, et al. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease[J\/OL]. Immunopharmacology and Immunotoxicology, 2021, 43(6): 666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493.","DOI":"10.1080\/08923973.2021.1973493"},{"issue":"3","key":"9082_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","volume":"36","author":"H Kato","year":"2024","unstructured":"Kato H, Kahlenberg JM (2024) Emerging biologic therapies for systemic lupus erythematosus[J\/OL]. Curr Opin Rheumatol 36(3):169. https:\/\/doi.org\/10.1097\/BOR.0000000000001003","journal-title":"Curr Opin Rheumatol"},{"issue":"14","key":"9082_CR56","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1177\/0961203320959702","volume":"29","author":"JWH Koh","year":"2020","unstructured":"Koh JWH, Ng CH, Tay SH (2020) Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials[J\/OL]. Lupus 29(14):1845\u20131853. https:\/\/doi.org\/10.1177\/0961203320959702","journal-title":"Lupus"},{"issue":"11","key":"9082_CR57","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40262-014-0175-9","volume":"53","author":"X Chen","year":"2014","unstructured":"Chen X, Hou Y, Jiang J et al (2014) Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis[J\/OL]. Clin Pharmacokinet 53(11):1033\u20131044. https:\/\/doi.org\/10.1007\/s40262-014-0175-9","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"9082_CR58","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"56","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y et al (2016) Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus[J\/OL]. J Clin Pharmacol 56(8):948\u2013959. https:\/\/doi.org\/10.1002\/jcph.686","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9082_CR59","doi-asserted-by":"publisher","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","volume":"34","author":"T Estevinho","year":"2023","unstructured":"Estevinho T, L\u00e9 AM, Torres T (2023) Deucravacitinib in the treatment of psoriasis[J\/OL]. J Dermatolog Treat 34(1):2154122. https:\/\/doi.org\/10.1080\/09546634.2022.2154122","journal-title":"J Dermatolog Treat"},{"key":"9082_CR60","doi-asserted-by":"publisher","unstructured":"KALUNIAN K C, FURIE R, MORAND E F, et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus[J\/OL]. Arthritis & Rheumatology (Hoboken, N.J.), 2023, 75(2): 253\u2013265. https:\/\/doi.org\/10.1002\/art.42392.","DOI":"10.1002\/art.42392"},{"key":"9082_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996662","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Cheng R, Liu Y (2022) Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review[J\/OL]. Front Immunol 13:996662. https:\/\/doi.org\/10.3389\/fimmu.2022.996662","journal-title":"Front Immunol"},{"key":"9082_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121766","volume":"289","author":"J Zhang","year":"2022","unstructured":"Zhang J, Guo Q, Dai D et al (2022) Rapamycin-encapsulated costimulatory ICOS\/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment[J\/OL]. Biomaterials 289:121766. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121766","journal-title":"Biomaterials"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09082-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09082-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09082-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:20:08Z","timestamp":1753266008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09082-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9082"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09082-x","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"11 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a secondary literature-based study, ethical approval is not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"70"}}